Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells

Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor... Cytotoxic T lymphocyte (CTL) peptide epitopes can be used for immunization of mice against lethal virus infection. To study whether this approach can be successful against virus‐induced tumors we generated a B6 (H‐2b) tumorigenic cell line transformed by human papillomavirus (HPV). This virus is detected in over 90% of all human cervical cancers. To identify vaccine candidates, we generated a set of 240 overlapping peptides derived from the HPV type 16 (HPV16) oncogenes E6 and E7. These peptides were tested for their ability to bind H‐2Kb and H‐2Db MHC class I molecules. Binding peptides were compared with the presently known peptide‐binding motifs for H‐2Kb and H‐2Db and the predictive value of these motifs is shortly discussed. The high‐affinity H‐2Db‐binding peptide and putative CTL epitope E7 49‐57 (RAHYNIVTF) was used in vaccination studies against HPV 16‐transformed tumor cells. Immunization with peptide E7 49‐57 rendered mice insensitive to a subsequent challenge with HPV 16‐transformed tumor cells in vivo, and induced a CTL response which lysed the tumor cells in vitro. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Immunology Wiley

Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells

Loading next page...
 
/lp/wiley/vaccination-with-cytotoxic-t-lymphocyte-epitope-containing-peptide-a14jkRB9Bp

References (43)

Publisher
Wiley
Copyright
Copyright © 1993 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim
ISSN
0014-2980
eISSN
1521-4141
DOI
10.1002/eji.1830230929
pmid
7690326
Publisher site
See Article on Publisher Site

Abstract

Cytotoxic T lymphocyte (CTL) peptide epitopes can be used for immunization of mice against lethal virus infection. To study whether this approach can be successful against virus‐induced tumors we generated a B6 (H‐2b) tumorigenic cell line transformed by human papillomavirus (HPV). This virus is detected in over 90% of all human cervical cancers. To identify vaccine candidates, we generated a set of 240 overlapping peptides derived from the HPV type 16 (HPV16) oncogenes E6 and E7. These peptides were tested for their ability to bind H‐2Kb and H‐2Db MHC class I molecules. Binding peptides were compared with the presently known peptide‐binding motifs for H‐2Kb and H‐2Db and the predictive value of these motifs is shortly discussed. The high‐affinity H‐2Db‐binding peptide and putative CTL epitope E7 49‐57 (RAHYNIVTF) was used in vaccination studies against HPV 16‐transformed tumor cells. Immunization with peptide E7 49‐57 rendered mice insensitive to a subsequent challenge with HPV 16‐transformed tumor cells in vivo, and induced a CTL response which lysed the tumor cells in vitro.

Journal

European Journal of ImmunologyWiley

Published: Sep 1, 1993

There are no references for this article.